World's First In-Utero Stem Cell Therapy for Fetal Spina Bifida Found Safe in Landmark Study
Original: First in-utero stem cell therapy for fetal spina bifida repair is safe: study View original →
A Breakthrough in Fetal Medicine
Researchers at UC Davis Health have achieved a historic milestone: the world's first in-utero stem cell therapy for spina bifida has proven safe in a Phase 1/2a clinical trial. Results published in The Lancet garnered over 240 upvotes on Hacker News and widespread attention from the medical community.
CuRe Trial Results
The CuRe Trial combined traditional fetal surgery with placenta-derived stem cells administered in utero. Key safety findings include:
- No adverse effects linked to stem cell treatment
- Zero infections, spinal fluid leaks, or abnormal tissue growth
- Complete wound healing in all surgeries
- MRI scans showed reversal of hindbrain herniation in all infants
- No patients required shunts for hydrocephalus before discharge
Why Spina Bifida Matters
Spina bifida is a congenital condition affecting approximately 1,500 to 2,000 U.S. children annually, caused by incomplete closure of the spinal canal during fetal development. While conventional fetal surgery has improved outcomes, many patients face long-term mobility challenges that this stem cell approach may help address.
What's Next
The trial is now enrolling up to 35 patients with follow-up evaluations through age 6. Principal Investigator Diana Farmer, MD, stated: "Putting stem cells into a growing fetus was a total unknown. We are excited to report great safety." This landmark result opens a promising new chapter in fetal medicine and regenerative therapy.
Related Articles
Google Research is attacking the weakest part of autonomous research agents: unverifiable papers. Its Science One Framework links every claim to evidence and reports zero phantom references where baselines reached 21%.
Anthropic is not only selling Claude Science as a research workbench. It says it wants to discover treatments for neglected diseases, raising a harder question: can a frontier AI lab become both a pharma software vendor and a drug developer?
The deal is worth up to about $600M, with roughly $60M in initiation fees, near-term payments, and milestones. Insilico will use Pharma.AI for early discovery while Takeda takes selected candidates into clinical validation and global development.